Among 10 analysts covering Qunar Cayman Islands Limited (NASDAQ:QUNR), 3 have Buy rating, 2 Sell and 5 Hold. Therefore 30% are positive. Qunar Cayman Islands Limited had 14 analyst reports since August 25, 2015 according to SRatingsIntel. The stock of Qunar Cayman Islands Ltd (NASDAQ:QUNR) has “Sell” rating given on Tuesday, October 27 by CLSA. The firm has “Hold” rating given on Thursday, March 17 by HSBC. The firm has “Sell” rating by CLSA given on Wednesday, May 4. On Tuesday, August 25 the stock rating was maintained by Summit Research with “Hold”. The rating was maintained by Pacific Crest on Tuesday, August 25 with “Overweight”. The firm has “Hold” rating given on Friday, October 30 by Stifel Nicolaus. The firm has “Hold” rating by Deutsche Bank given on Friday, March 18. The firm earned “Equal-Weight” rating on Tuesday, April 26 by Morgan Stanley. The firm has “Sell” rating by Credit Agricole given on Tuesday, October 27. The firm has “Buy” rating by Stifel Nicolaus given on Friday, August 28. See Qunar Cayman Islands Ltd (NASDAQ:QUNR) latest ratings:
The stock of FibroGen Inc (NASDAQ:FGEN) is a huge mover today! About 342,742 shares traded. FibroGen Inc (NASDAQ:FGEN) has risen 29.23% since September 20, 2016 and is uptrending. It has outperformed by 17.65% the S&P500.The move comes after 9 months positive chart setup for the $1.83B company. It was reported on Apr, 27 by Barchart.com. We have $31.01 PT which if reached, will make NASDAQ:FGEN worth $164.70 million more.
It is down 1.47% since July 25, 2016 and is uptrending. It has underperformed by 10.11% the S&P500.
Qunar Cayman Islands Limited is engaged in offering mobile and online commerce platform for travel in China. The company has market cap of $4.44 billion. The Firm offers a range of travel products, including flights, hotels, vacations packages, attraction tickets and other travel related offerings. It currently has negative earnings. The Firm offers Qunar Travel, which is a mobile application that enables its users to search for and purchase travel products.
Analysts await FibroGen Inc (NASDAQ:FGEN) to report earnings on May, 8. They expect $-0.63 EPS, down 40.00% or $0.18 from last year’s $-0.45 per share. After $-0.54 actual EPS reported by FibroGen Inc for the previous quarter, Wall Street now forecasts 16.67% negative EPS growth.
FibroGen, Inc. is a science-based biopharmaceutical company. The company has market cap of $1.83 billion. The Firm is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. It currently has negative earnings. The Company’s lead product candidate is roxadustat .
